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INVESTIGATION OF P-GLYCOPROTEIN (PGP) INDUCTION BY PGP SUBSTRATES TO
INDUCE PACLITAXEL RESISTANCE IN OVARIAN CANCER CELLS
Ryker Penn
University of the Incarnate Word, 2019
The purpose of this study was to investigate the development of chemotherapeutic
resistance to paclitaxel in ovarian cancer cells after treatment with drugs that are substrates for Pglycoprotein (PGP). A core concept of this experiment was to identify if PGP substrate drugs
could also act as PGP inducers after prolonged treatment in SKOV-3 ovarian cancer cells. In
order to test this, SKOV-3 cells were exposed to either fexofenadine, a PGP substrate used as an
antihistamine, or the chemotherapeutic drug vinblastine. After 42 days of drug treatment, ABCB1
gene expression was measured by qRT-PCR. Analysis of ABCB1 expression in treated cells
revealed that fexofenadine was unable to significantly induce gene expression in SKOV-3 cells.
Although some cells treated with vinblastine did exhibit some significant increases in ABCB1
expression, vinblastine exposure overall could not reliably induce ABCB1 gene expression within
SKOV-3 cells. After testing for PGP induction, treated cells were exposed paclitaxel and tested
for cell survivability. The results indicated that cells with induced PGP exhibited reduced
survivability against paclitaxel exposure.
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Ovarian Cancer affects around 204,000 women a year all over the world and of those it is
responsible for nearly 125,000 deaths. In the United States alone approximately 22,000 new
cases manifest each year leading to more deaths than any other type of female reproductive
cancer (12). These statistics are bolstered by the fact that nearly 70% of ovarian cancers are
diagnosed at an advanced stage the result being that women with this diagnosis can at best only
expect to survive for another 5 years. This poor diagnosis has led to this form of cancer being
known as a ‘silent killer’ as it shows very few symptoms until after it metastasizes within the
peritoneal cavity of the patient (2). Similar to other cancers which are often detected in advanced
stages, cancerous cells often develop drug resistance which renders numerous chemotherapeutics
largely ineffective against the disease and forces doctors to treat patients with other medications
that may prove less effective (2).
The development of this resistance within cancerous tissues to chemotherapeutic drugs is
known as multidrug resistance (MDR) and it represents a grave threat to the efficiency of most
widely used chemotherapy agents (15). It was discovered nearly 40 years that MDR played a
vital evolutionary role in an animal’s defense against environmental toxins by mobilizing cellular
efflux pumps present on the cell membrane to pump out invading toxic substances (19). The
overexpression of these pumps in cancerous cells however is what causes this normally
advantageous mechanism to work against the greater good of a cancerous body essentially
rendering many chemotherapeutic drugs ineffective. A significant mechanism which confers
resistance to cancer is their active removal of the chemotherapeutic drugs from the cancer cells
by drug transporters in the ATP Binding Cassette (ABC) family. Those that have been found to
be associated with MDR include P-glycoprotein (PGP), Multidrug Resistance Proteins (MRPs),
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and Breast Cancer Resistance Protein (BCRP) but this proposed project will focus specifically on
the role of PGP in drug resistance (15).
PGP Is a 170-kDA ABC transporter comprised of 1280 amino acids which acts as an
ATP energy dependent efflux pump. It is encoded by the ABCB1 gene, alternatively known as
MDR1, which is present on chromosome 7q21 (3). It has 2 symmetrical amino and carboxyl
halves known as cassettes which consist of 6 transmembrane domains (TMDs) each. These
TMDs are the channels by which cells utilize these binding cassettes to power the expulsion of
cytotoxic drugs out of the cell to by hydrolyzing ATP. This action effectively reduces
intracellular drug concentrations. The ABCs are linked together by a polypeptide loop of about
80 amino acids with an ATP-binding motif (3). There are 2 ATP binding domains (alternatively
known as Nucleotide Binding Domains) which power PGP function and they are both located in
the cytoplasm and function to transfer energy to transport substrates across the membranes. Both
NBDS are essential for the ability to bind drugs to the binding sites located on the extracellular
surface of the protein (18). These drug binding sites are known to be quite mobile and likely
adjust based on different drugs employing a mechanism known as ‘substrate-induced fitting’ (1).
This flexibility is what allows them to be involved in so many processes of the body and to have
effects against such a diverse array of drugs with dissimilar structures (3).
PGP is expressed in the lining of the gastrointestinal tract and endothelial cells of the
blood brain barrier. It is also present in many other tissues including the bile duct, adrenal gland,
kidney tubules, small intestine, pancreatic duct, heart, lungs, spleen, certain skeletal muscles, and
the ovarian blood barrier (4). PGP functions by pumping the drugs out of the cells after oral
ingestion due to its station in the apical membranes of enterocytes of the intestine. Then when
the drugs enter systemic circulation, PGP aids in the removal of these drugs through urine and

9
bile due to its presence on hepatocytes and the apical surface of the kidney’s tubular cells (4).
PGP also appears to regulate hormone distribution and may regulate cell differentiation,
proliferation, immune responses and programmed cell death otherwise known as apoptosis (1).
In healthy cells, P-glycoprotein mediated drug efflux is believed to occur based on one of
three possible mechanisms. The first is known as the classical pore pump model and it has PGP
forming a hydrophilic tunnel by which recognized substrates are exchanged from the cytosol into
the extracellular media. The second method is called the hydrophobic vacuum cleaner model and
it has PGP binding directly with hydrophobic substrates within the inner side of the plasma
membrane and then expelling them out of the cell upon identifying them as xenobiotic in nature
The substrates are held between the internal aqueous compartment and the inner membrane
surface of the cell before PGP makes contact which then results in conformational alterations to
the transporter itself to remove the substrate to the external medium (5). The third and final
model is the most accepted of the three, it is called the flippase model and it has PGP
intercepting the drug as it travels through the lipid membrane and flipping the drug from the
inner leaflet (the inner side of the plasma membrane) toward the outer leaflet (the outer side of
the plasma membrane) against the concentration gradient via ATP hydrolysis (18).
There are four primary mechanisms of drug resistance. The first is enhanced efflux of a
drug by proteins such as the aforementioned ABC family of efflux pumps including Pglycoprotein. Other efflux transporters include the Breast Cancer Resistance Protein and the
Multidrug Resistance Proteins 1-3. The second method of drug resistance is through the
modulation of drug-induced apoptotic progression in which PGP may also be involved. The third
method involves the development of changes in the cell’s ability fix DNA damage due to genetic
variance in the coding for repair proteins of drug-targeted molecules (1). The fourth and final
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method is the acceleration of drug metabolism by enzymes such as glutathione S-transferase or
GST. It is generally accepted that MDR is most often the result of multiple of the above methods
occurring together but the most prevalent method associated with multidrug resistance is the
enhanced efflux by ABC family pumps (1).
In addition to the methods above, there are some unique chemotherapeutic drugs which
cannot be transported by PGP whose use can result in the manifestation of the MDR phenotype
through other more unconventional means. In the unique case of cisplatin-induced PGP
expression, the drug can act as a ligand to the xenobiotic detecting pregnane X receptor (PXR)
which has been shown to have a degree of transcriptional control over PGP (1,16). In this way,
the development of drug resistance to cisplatin in cancer cells is an indirect method of resistance
to PGP rather than a direct link to the pump itself (6, 15). This PXR-mediated PGP
overexpression has further been associated with resistance to both paclitaxel and vinblastine in
LS180 colon cancer cells (9).
In cancerous cells, drug resistance conferred by the expulsion of drugs from the cells by
ABC transporters such as PGP, BCRP, and numerous other MRPs. The overexpression of PGP
can greatly diminish the intracellular retention of these therapeutic agents (15). In recurrent
ovarian cancer cases the changes in ABCB1 expression is assessed as PGP has been proposed as
a viable biomarker for drug resistance in cancer patients (22). Further, induced PGP expression
has been detected in tumors exposed common drugs which act as immunosuppressants,
antihypertensives, antihistamines, antimicrobials, and anti-inflammatories (16). Due to the high
diversity of drugs that are recognized and transported by PGP however there are also many
therapeutic drugs which are known to act as both PGP substrates and inhibitors which include
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calcium channel agonists, calmodulin antagonists, local anesthetics, steroids, protein-kinase
inhibitors, detergents, and other immunosuppressive agents (1).
The most efficacious chemotherapeutic drugs used in the treatment of ovarian cancer
today are cisplatin, its analogue carboplatin, and paclitaxel which all are commonly administered
together in a treatment regimen (12). An issue with these treatments however is that resistance
may develop to these drugs, ultimately leading to treatment failure. While cisplatin can develop
resistance using the unique PXR-related methodology mentioned earlier, cancer cell resistance to
paclitaxel has primarily been found to be mediated through ABC proteins such as PGP (15).
Another anti-cancer chemotherapeutic drug of interest is vinblastine which is a vinca alkaloid
used as a cytotoxic agent to treat patients with lymphoma, leukemia, ovarian cancer, breast
cancer, colorectal cancer, as well as other types of solid tumors. Like paclitaxel, vinblastine is a
known PGP substrate which has been shown to be capable of inducing PGP (9). The common
antihistamine fexofenadine (commercially known as Allegra) is also a known PGP substrate
which also may be capable of PGP induction (personal communication, Dr. Christopher Farrell).
In recent years however, research has been done using cancer cell lines to identify drugs
which can act as substrates for PGP. These medications that are commonly used by patients for
co-morbidities may cause an induction of PGP expression in cancer cells, possibly conferring
resistance to chemotherapeutics used to treat those tumors. The purpose of this experiment was
to induce the expression of PGP in the ovarian cancer cell line SKOV-3 using the PGP substrates
fexofenadine and vinblastine and then to determine if the PGP-induced SKOV-3 cells display
primary drug resistance to paclitaxel. We hypothesize that when ovarian cancer cells are exposed
to these PGP-substrate drugs the cancer cells will begin to overexpress the P-glycoprotein
transporter and will then display drug resistance.
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Materials and Methods
Reagents
The drug vinblastine acted as a positive control and fexofenadine served as the test PGP
inducer, both were purchased from Sigma Aldrich. The chemotherapeutic paclitaxel used to
determine drug resistance in PGP expressed cancer cells was purchased from Sigma Aldrich. The
SKOV-3 human ovarian cancer cell line and RPMI 1640 medium used to culture them were
purchased from ThermoFisher Scientific along with 10% Fetal Bovine Serum. When subculturing cells, Trypsin 0.53 mM EDTA solution was purchased from ATCC and used to
disperse cell layers before the new medium is added. In preparation for performing quantitative
real-time PCR (qRTPCR), the Purelink RNA Mini kit was purchased from Thermofisher for
RNA isolation along with the SuperScript II Reverse Transcriptase kit for cDNA synthesis from
Invitrogen. Taqman Advanced Master Mix and custom assays for HPRT1 and ABCB1 were
purchased from ThermoFisher Scientific. Additionally, dNTPs and random hexamer primers for
expression profiling were purchased from Invitrogen. To determine cell viability the PrestoBlue
Cell Viability Assay kit was purchased from ThermoFisher Scientific.
Cell Culture
The SKOV-3 cells were maintained as monolayers in complete RPMI 1640 medium with
10% fetal bovine serum. SKOV-3 cells were grown for three passages before beginning any drug
exposures. After the third passage, all cells were given at least seven days of growth in the
incubator with media changeout at least twice per week depending on cellular health. The cells
were contained in either T.75 flasks or 75mm petri dishes and stored in a 151L CO2 incubator set
to 5% and 37ºC.
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Dose Response Curve
To determine drug concentrations of fexofenadine and vinblastine for use in the induction
studies which could maintain cellular health, a dose response curve was performed using
separate groups of SKOV-3 cells. Each group was treated with one of three concentrations of
either vinblastine or fexofenadine. Vinblastine and Fexofenadine were solubilized in DMSO first
and then diluted into water. Vinblastine was prepared at concentrations of 2nM, 10nM and 30nM
with in a final DMSO concentrations of 4.732e-7%, 1.23e-5%, and 0.0001% respectively.
Fexofenadine was prepared at concentrations of 25μM, 75μM, and 125μM with in a final DMSO
concentrations of 0.005%, 0.68%, and 1.3% respectively. The cells were then cultured for a week
with media changes on day 3 and 5. These drug concentrations were based on previous research
in PGP induction with the same drugs and through email correspondence with Dr. Christopher
Farrell (7, 8). Treated cells then were harvested and assessed for cell viability using the
PrestoBlue assay. The highest concentration which maintained cellular viability for each drug
was selected to continue on with the induction study. Cellular viability was based on the visual
health of the populations as determined by cell confluence and number of dead cells counted in
the media. Results from PrestoBlue experiment was analyzed using an Infinite M200 Pro-Tecan
plate reader at the University of the Incarnate Word.
PGP Induction
Based on results from the dose response curve the 75μM fexofenadine and 2nM
vinblastine concentrations were chosen for the PGP induction studies. The DMSO vehicle
controls were prepared at a concentration of 0.68%, this matches the 75μM fexofenadine
exposure as this is highest DMSO content of all treatments. The induction study was repeated
three times with each exposing SKOV-3 cells to drug conditions for 42 days. Within each study
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the drug exposures were performed in triplicate. The intent was to have media changeout
occurring every three days and RNA isolation every seven days. Because of differences in cell
growth rate due to drug exposure however some timepoints were moved to allow for additional
days of growth. Throughout all 3 studies untreated control cells were maintained with RNA
isolation taken at the beginning and end of each induction study.
qRTPCR
After each induction study had concluded the isolated RNA collected from the cells was
analyzed for signs of PGP induction utilizing qRT-PCR. The isolated mRNA was used to
synthesize cDNA using the Superscript II Reverse Transcriptase kit from Invitrogen. Expression
of ABCB1 was evaluated with customized Taqman Gene Expression Assays purchased from
Thermofisher Scientific for ABCB1 (Hs00184500_m1) and the housekeeping gene HPRT1
(Hs01003267_m1). Expression was detected using fluorescent probes for ABCB1 and HPRT1
with a Bio-Rad C1000 Touch Thermocycler. The CT values provided by the thermocycler were
then used the analyze the ABCB1 gene expression relative to the expression of the housekeeping
gene HPRT1, this is known as the delta cycle threshold (ΔCT) value. The ΔCT values for each
exposure was additionally compared to the values from the untreated controls.
Delta Ct = Ct gene test – Ct endogenous control
Paclitaxel Resistance
After each induction study concluded the treated SKOV-3 cells were exposed to
paclitaxel to assess if PGP induction could confer resistance to the chemotherapeutic drug.
Paclitaxel was solubilized in DMSO and then diluted into water. The paclitaxel concentrations
for these experiments were 0.1µM and 1µM with in a final DMSO concentrations of 0.0016%
and 0.0169% respectively. SKOV-3 cells were plated onto a 96-well plate and exposed to RPMI
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media with either 0.1µM and 1µM paclitaxel for 24 hours. After this period the cells were then
tested for cell viability using the PrestoBlue Cell Viability Assay. Results from PrestoBlue
experiment was analyzed using an Infinite M200 Pro-Tecan plate reader at the University of the
Incarnate Word. This experiment was only performed at the conclusion of the second and third
PGP induction studies.
Data Analysis and Statistics
The ΔCT values produced by the PCR machine were used to examine PGP expression for
each study. At each timepoint, results from every exposure group was analyzed using a Student’s
t-test as compared to the untreated controls collected at the start of each study. Statistical analysis
was performed in SPSS version 24 and Microsoft Excel 2016. Cell viability data gathered using
the PrestoBlue assay after paclitaxel exposure was evaluated by comparing results to the
untreated control cells.
Results
ABCB1 Expression in Treated SKOV-3 Cells
The expression level of ABCB1 was investigated to determine if treatment with 75µM
fexofenadine or 2nM vinblastine could induce ABCB1 expression in SKOV-3 cells. The ∆Ct
values normalizes the expression of ABCB1 to that of the housekeeping gene HPRT1.
Significance for each ∆Ct value was determined through comparison against the day 0 untreated
controls. All of the 0.68% DMSO vehicle control samples exhibited a statistically significant
decrease in ABCB1 expression with samples collected from day two and four showing the
sharpest decline (p > 0.001) (Figure 1). The remainder of the DMSO samples displayed a
statistically significant decrease of (p > 0.05) in ABCB1 expression. Samples treated with 75µM
fexofenadine were observed to have a statistically significant decrease in ABCB1 expression on
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day 14 (p > 0.001) and day 31 (p > 0.05). None of the fexofenadine treated samples exhibited
any significant signs of ABCB1 induction (Figure 1). The 2nM vinblastine treated cells displayed

Relative ABCB1 Expression (∆Ct)

no significant increase in ABCB1 expression throughout the study (Figure 1).
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Expression Analysis of ABCB1 in Study 1 SKOV-3
Cells
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Figure 1. Expression analysis of ABCB1 in drug treated SKOV-3 cells from the first induction
study as measured by qRT-PCR. Chart utilizes ∆Ct values which compare ABCB1 expression to
that of the endogenous control gene HPRT1. Values were compared with the day 0 untreated
cells to determine significance and were considered significant at *p < 0.05, **p < 0.01 and ***p
< 0.001.
The second induction study was carried out using the same treatments as previously
described with the addition of untreated cells which ran concurrently to the other treatments and
had RNA isolated on day zero and day 56. The cells from the DMSO vehicle controls were
observed to have a significantly significant decrease (p > 0.05) in PGP expression starting from
day 15 until the end of the test period (Figure 2). The 75µM fexofenadine treated samples from
day four exhibited statistically significant decrease (p > 0.05) in PGP expression. All remaining
samples treated with fexofenadine did not indicate any significant signs of ABCB1 induction
(Figure 2). The 2nM vinblastine treated cells displayed a statistically significant decrease (p >
0.05) in ABCB1 expression in samples starting from day 15 until the end of the test period
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(Figure 2). The vinblastine treated cells displayed ABCB1 expression levels beneath that of the

Relative ABCB1 Expression (∆Ct)

other treatments for the duration of the study.
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Expression Analysis of ABCB1 in Study 2 SKOV-3
Cells
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Figure 2. Expression analysis of ABCB1 in drug treated SKOV-3 cells from the second
induction study as measured by qRT-PCR. Chart utilizes ∆Ct values which compare ABCB1
expression to that of the endogenous control gene HPRT1. Values were compared with the day 0
untreated cells to determine significance and were considered significant at *p < 0.05, **p < 0.01
and ***p < 0.001.
The third induction study utilized the same drug treatments as the previous studies and
maintained a population of untreated control cells which had RNA isolated on day zero and 42.
On day 42 of the study the DMSO vehicle samples displayed a statistically significant decrease
(p > 0.01) in ABCB1 expression (Figure 3). The 75µM fexofenadine treated cells were observed
to statistically significantly decrease (p > 0.01) in samples collected from day 21 (Figure 3).
Additionally, fexofenadine treated samples from day 42 displayed a statistically significant
decrease (p > 0.001) in ABCB1 expression. Both the DMSO vehicle and 75µM fexofenadine
treated cells overall maintained a steady decrease in ABCB1 expression throughout the study.
The 2nM vinblastine treated cells exhibited a statistically significant increase (p > 0.05) in
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ABCB1 expression on samples from day 14. Vinblastine treated cells also displayed a significant

Relative ABCB1 Expression (∆Ct)

decrease (p > 0.05) in ABCB1 on day 42 (Figure 3).
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Expression Analysis of ABCB1 in Study 3 SKOV-3
Cells
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Figure 3. Expression analysis of ABCB1 in drug treated SKOV-3 cells from the third induction
study as measured by qRT-PCR. Chart utilizes ∆Ct values which compare ABCB1 expression to
that of the endogenous control gene HPRT1. Values were compared with the day 0 untreated
cells to determine significance and were considered significant at *p < 0.05, **p < 0.01 and ***p
< 0.001.
Resistance to Paclitaxel in Treated SKOV-3 Cells as Determined by PrestoBlue Viability
Assay
In order to assess if PGP induction could result in the development of drug resistance the
treated SKOV-3 cells were then exposed to paclitaxel. After the SKOV-3 cells from the second
induction study were treated for 42 days with each drug condition, they were removed from the
fexofenadine or vinblastine exposure and then exposed one of two different concentrations of
paclitaxel and tested for cell viability on Day 51. The charts below reflect the absorbance of
PrestoBlue as compared to media only controls, groups with higher absorbance indicate superior
survival against paclitaxel exposure. Based on the recommendation of the protocol provided by
Thermofisher, cell viability was detected after 20 minutes of incubation. For the 0.1µM
paclitaxel exposure experiment, the DMSO control and 2nM vinblastine treated cells overall
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exhibited similar survival when compared to the untreated controls. The 75µM fexofenadine
cells had the worst survival with absorbance nearly half of that of untreated controls (Figure 4a).
For the 1µM paclitaxel exposure experiment, all groups exhibited lower survival than the
previous 0.1µM exposure. The 2nM vinblastine treated samples showed the highest survival of
all treatments (Figure 4b). The untreated control cells had the second-best survival falling just
behind the vinblastine cells. Both the DMSO control and 75µM fexofenadine treated cells both
displayed poor survivability when compared the vinblastine cells exposed to the same paclitaxel
treatment (Figure 4b).
4a

Cellular Viability of Study 2
Cells Exposed to 0.1µM
Paclitaxel

4b

0.6

Survival (Absorbance)

0.6

Survival (Absorbance)

Cellular Viability of Study 2
Cells Exposed to 1µM
Paclitaxel
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0.5
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0.3
0.2
0.1
0

0
Control
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Control

DMSO

Fexofenadine

Vinblastine

Fexofenadine

Vinblastine

Figure 4. Cell viability analysis of treated SKOV-3 cells after exposure to paclitaxel to ascertain
presence of resistance to chemotherapeutic treatment. SKOV-3 cells from the second induction
study (Day 51) were exposed to 2 different concentrations of paclitaxel and measured for cell
viability after 20 minutes using PrestoBlue assay. The media corrected absorbance values were
read at 570 nm and normalized to the 600 nm values. Cells exhibiting resistance to paclitaxel
should have greater cell viability. (a) Treated SKOV-3 cells exposed to 1µM of Paclitaxel. (b)
Treated SKOV-3 cells exposed to 0.1µM of Paclitaxel.
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After the third induction study had concluded the cells were exposed to 0.1µM of
paclitaxel the DMSO treated samples exhibited the greatest survival of all treatments. The
untreated control and 75µM fexofenadine treated cells exposed to paclitaxel exhibited very
similar survival with the untreated controls showing slightly greater absorbance. The 2nM
vinblastine treated cells fared the worst with survival lower than any of the other treatments
(Figure 5b). SKOV-3 cells exposed to 1µM of paclitaxel displayed similar trends to those found
in the 0.1µM paclitaxel exposure. The greatest overall survival took place in the DMSO control
samples (Figure 5b). The fexofenadine treated cell had very similar survival to the DMSO
controls while the untreated control cells fared slightly worse. Cells treated with 2nM vinblastine
had the worst survival with an absorbance less than half of any other treatment exposed to the
same Paclitaxel dose (Figure 5b).
Discussion
This study aimed to investigate the expression of ABCB1 in SKOV-3 ovarian cancer cells
after treatment with vinblastine and fexofenadine, drugs identified as PGP substrates. Vinblastine
is a powerful chemotherapeutic drug which has a documented history as a PGP inducer, and
thus, it was selected as a positive control for this study (13, 16). Fexofenadine is an over-thecounter antihistamine commonly used to relieve allergy symptoms that is also a known PGP
substrate (16). Fexofenadine was chosen for this study because of the implications this drug
could have for patients before a cancer diagnosis. If treatment with fexofenadine can alter
ABCB1 expression and its associated regulatory mechanisms in cancer cells it could impact the
efficacy of chemotherapeutic drugs like paclitaxel. PGP induction specifically has been
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Cellular Viability of Study 3
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Figure 5. Cell viability analysis of treated SKOV-3 cells after exposure to paclitaxel to ascertain
presence of resistance to chemotherapeutic treatment. SKOV-3 cells from the third induction
study (Day 51) were exposed to 2 different concentrations of paclitaxel and measured for cell
viability after 20 minutes using PrestoBlue assay. The media corrected absorbance values were
read at 570 nm and normalized to the 600 nm values. Cells exhibiting resistance to paclitaxel
should have greater cell viability. (a) Treated SKOV-3 cells exposed to 1µM of Paclitaxel. (b)
Treated SKOV-3 cells exposed to 0.1µM of paclitaxel.
identified as the target of an ever-growing number of inquiries involving the development of
drug resistance. While the resulting alterations in gene expression through drug exposure could
be transient in nature when produced in a lab environment, the acquisition of drug resistance
through ABC transporter expression remains a relevant concern with the clinical community (23,
24).
Across all three PGP induction studies performed in this experiment, both the
fexofenadine and DMSO vehicle controls consistently did not induce significant ABCB1
induction. Results from the second and the third studies further indicate that both the
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fexofenadine and DMSO controls display ABCB1 levels beneath that of untreated cells. The
consistently similar results displayed by these two groups could be due to the fact that both
exposures had the same 0.068% DMSO content. The vehicle controls were calculated to have the
same percentage of DMSO as was used to make the 75µM fexofenadine exposure. Despite the
similarity between these results, the DMSO vehicle cells in all three induction studies
consistently exhibited more change with an overall negative trend as each study proceeded.
Although the final DMSO concentration in these samples was beneath the recommended 0.1%, it
is possible that the DMSO content was still enough to cause the PGP expression in SKOV-3 cells
to fall. As this same amount of DMSO was used to solubilize fexofenadine in this study, this
could indicate that the potential induction effects of fexofenadine exposure could have been
counteracted by the toxicity of the DMSO. This conclusion however would require further
investigation to verify.
The vinblastine treated cells from the first and third induction studies were the only
exposures to demonstrate an increase in ABCB1 expression. In the case of the first study however
the values were not significant. The only vinblastine treated cells which did exhibit a significant
increase in ABCB1 expression was from the third induction on day 15. Subsequent samples from
the third induction study actually began to show a decrease with ABCB1 expression dipping
beneath the untreated controls by the final day of the experiment. This could be a result of the
transient nature of drug-induced ABCB1 induction documented in a study by Miklos et al which
utilized SW480 cells. In a study published in the Journal of the National Cancer Institute,
researchers further designated vinblastine specifically as a chemotherapeutic additionally capable
of inducing stable ABCB1 expression in K562 cells, but not within HL-60 leukemia cells (24).
The diversity of results vinblastine exposure can have among different cell types could
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contribute to answering why exactly vinblastine failed to act as a reliable positive control in this
study.
The results from the vinblastine treated cells in second induction study were very
different than the other two studies as they displayed a notable decrease in ABCB1 expression
which did not level out until the third week of the study on Day 21. Like the third study all drug
treated cells had lower ABCB1 expression when compared to the untreated SKOV-3 cells. This
downward trend in the early days of the study may be related to an incident which occurred on
the 10th day of the study during which the incubator failed and was no longer supplying CO2.
During the transfer to a functioning incubator the cells were outside of a controlled environment
for more than five hours. When this occurred the first and second induction studies were both
running concurrently so the incubator had flasks with cells from both studies. The reason
however that one does not see the possible implications of this incident in the first study is
because the second study was started two weeks after the first. By day 10, the cells from study
two had only experienced three days of growth since their last passage. The cells from the first
study on the other hand were on day 27 and had already experienced a full week of growth since
their last passage. To compensate for this the cells from both studies were given extra time to
grow in an incubator at a separate facility as both were unable to reach confluence on schedule.
Although this may have had an adverse effect on the cellular growth rate and morphology it
cannot be fully concluded that the downward expression of ABCB1 displayed was directly the
caused by the incubator malfunction.
After generating a best fit trendline for all of the ∆Ct values with each condition for all
three studies, the slopes of each line were analyzed to see the overall trend of how each treatment
affected the cells. Trendlines for DMSO and fexofenadine treated cells in all three studies were
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negative, meaning that the drugs overall decreased the expression of ABCB1 in SKOV-3 cells.
While extremely similar, these negative trends do not deviate far from ABCB1 expression in
untreated cells on shown on day zero (Figure 6a, 6b, 6c). This indicates that DMSO and
fexofenadine treatments did not induce significant change in our SKOV-3 cells after 42 days of
exposure. Trendlines generated for the vinblastine treated cells exhibit a notable degree of
difference from study to study with only the first study having a positive trend towards ABCB1
induction (Figure 6a). Similar to the first study, the trendline for the vinblastine treated cells in
the third study also stays above that of the DMSO control and fexofenadine cells (Figure 6c).
The trendline generated from the second study however exhibits a noticeable negative slope
when compared to both the other treatments in the same study and the other vinblastine
treatments from the other studies (Figure 6b). This statistically significant (p < 0.05) decline in
ABCB1 expression requires further exploration to properly explain.

Study 1 ∆Ct Trendline Analysis
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Figure 6a. Trendline expression analysis of ABCB1 in drug treated SKOV-3 cells from the first
induction study as measured by qRT-PCR. Utilizes ∆Ct values to generate best fit trendlines to
visualize overall effects of each treatment on ABCB1 expression.
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Study 2 ∆Ct Trendline Analysis
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Figure 6b. Trendline expression analysis of ABCB1 in drug treated SKOV-3 cells from the
second induction study as measured by qRT-PCR. Utilizes ∆Ct values to generate best fit
trendlines to visualize overall effects of each treatment on ABCB1 expression.

Study 3 ∆Ct Trendline Analysis
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Figure 6c. Trendline expression analysis of ABCB1 in drug treated SKOV-3 cells from the third
induction study as measured by qRT-PCR. Utilizes ∆Ct values to generate best fit trendlines to
visualize overall effects of each treatment on ABCB1 expression.
In order to statistically examine the reproducibility of PCR results across the three
induction studies, the confidence intervals were identified for the slopes of each treatment’s best
fit trendline across all of the induction studies. Using a linear regression model, Appendix A
shows the results of this analysis which was conducted in IBM SPSS (Statistical Package for the
Social Sciences). If the slope of each trendline all fit into the same 95% confidence intervals,
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then there is insufficient evidence to conclude that the slope of each line differs significantly.
The slope lines for fexofenadine treated cells from study one and three do not differ
significantly; thus, there is insufficient evidence to say that the results of these treatments differ
in SKOV-3 cells. The slope line of the fexofenadine cells from the second induction study does
somewhat overlap with that of the first, but not of the third study. This indicates that the cells
between the second and third study do show significantly different results from their respective
treatments. The slopes generated for DMSO-treated cells all overlap meaning that there is
insufficient evidence to conclude that results of this exposure differed between the three studies
for this treatment. Finally, the slopes generated from the trendlines in vinblastine treated cells
overlapped in cells from study one and three. This indicates that the change in ABCB1 expression
did not differ in a significant way between cells of those studies. The slope for vinblastine treated
cells in study two, however, does differ significantly from the similarly exposed cells from either
the first or third studies. This variance present in the results SKOV-3 cells indicates the need for
further testing as to whether either substrate could reliably induce PGP in SKOV-3 cells.
While the data was unable reliably demonstrate fexofenadine or vinblastine induced
ABCB1 expression in our SKOV-3 cells, the idea of PGP substrate drugs possibly acting as
inducers remains a query worth exploring. Across numerous cell types, the expression of ABCB1
has been shown to play a role in the absorption and secretion of numerous anticancer drugs (10).
The anticancer drug vinblastine’s association with ABCB1 expression especially seems
noteworthy based on findings of studies which utilize other cell types. For example, a study
performed by Harmsen et al. in 2010 utilized a LS180 colon cancer cell line to verify that
anticancer drugs, such as paclitaxel and vinblastine could induce PXR-mediated PGP
overexpression. (9). Another study which utilized human neural stem/precursor cells (hNSPCs)
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found that treatment with vinblastine resulted in the drug-induced expression of ABCB1 (13).
Using a SW840 colon cancer cell line with known ABCB1 overexpression, Miklos et al.
attempted to verify the impact ABCB1 expression could have on resistance to the
chemotherapeutic triapine, which itself is a substrate of PGP. While they concluded that triapine
was only a weak substrate for PGP, they did interestingly find that treatment with triapine
resulted in the upregulation of ABCB1 in their SW840 colon cancer cells. They concluded that
this upregulation was due to the stress the cells underwent with exposure to triapine (23).
Whether or not SKOV-3 cells could exhibit a comparable mechanism that could alter ABCB1
expression when under similar pressure may be a topic worth further investigation.
In addition to any ABCB1 gene expression effects, some of the drug treatments utilized in
this study did have an observable effect on the morphology and health of the SKOV-3 cells. The
normal untreated SKOV-3 cells, as well as those treated with 0.068% DMSO, had a ‘spiderlike’
structure that when plated with two million cells would reach confluence inside of a T-75 flask
after seven days (Figure 7a, 7b). Using the official ATCC documentation on the cells as well as
the untreated controls as a baseline for average SKOV-3 growth patterns, the 75µM fexofenadine
treated cells appeared to display somewhat augmented growth. A T-75 flask of untreated cells
generally was expected to be confluent within a week but fexofenadine treated cells often would
reach confluence in as few as five days despite being initially plated with the same number of
cells. While these flasks would of course yield much higher cell counts than the other treatments
the morphology of the SKOV-3 cells would remain largely unchanged (Figure 7c). The 2nM
vinblastine treated cells developed an irregular globular shape that would form clusters or islands
of growth rather than spread out across the plate (Figure 7d). In addition to these new
characteristics, the vinblastine treated cells often were in poor health and low confluence after
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each week, sometimes requiring a higher plating density of cells to even make the required
numbers of cells for each week of the experiment. While this obviously is tied to the potency of
vinblastine as a chemotherapeutic agent the effect this more extreme environment could have
resulted in innumerable changes on the gene expression of the SKOV-3 cells. The exact relation
between the health of the cells, as indicated by higher cell counts or changes in their
morphology, and the expression of ABCB1 remains unknown and requires further investigation.
7a

7b

7c

7d

Figure 7. SKOV-3 cells imaged under each under each treatment after 5 days of growth within a
CO2 incubator. (a) Untreated SKOV-3 cells. (b) 0.068% DMSO treated SKOV-3 cells. (c) 75µM
fexofenadine treated SKOV-3 cells. (d) 2nM vinblastine treated SKOV-3 cells.
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The second aim of this experiment was to identify if SKOV-3 cells with augmented
ABCB1 expression would exhibit resistance to treatment with the chemotherapeutic drug
paclitaxel, which itself is a PGP substrate. In the cells taken from the second induction study,
there was a notable difference in the survivability between the cells of each paclitaxel exposure,
with the primary commonality being that the fexofenadine treated cells proved most susceptible
to the cytotoxic effects of the drug under both conditions. In the cells from the second study
exposed to 1µM paclitaxel, the greatest survivability was found in vinblastine treated cells. The
next greatest survivability to 1µM paclitaxel was in the untreated control cells followed by the
fexofenadine and lastly the DMSO treated cells. The cells from the second study exposed to
0.1µM displayed markedly different results from the 1µM cells with the untreated control cells
showing the strongest survivability. The DMSO and vinblastine treated cells trail just behind the
untreated cells with notable survival towards paclitaxel while the fexofenadine treated cells again
fared the worst. Based on the expression analysis from these cells the DMSO and fexofenadine
treated cells showed no significant signs of ABCB1 induction so it unlikely that their
susceptibility to paclitaxel treatment was related to that factor. Furthermore, the untreated
baseline cells in both experiments exhibited both higher levels of ABCB1 than all other
treatments. While noteworthy these trends are hardly consistent as the ABCB1 expression in
baseline cells is not significantly induced. The ABCB1 expression in the vinblastine treated cells,
which fared best against the 1µM paclitaxel exposure, additionally displayed greatly reduced
gene expression which taken altogether indicates the need for further testing.
In cells taken from the third induction study, the untreated, DMSO, and fexofenadine
exposed cells all exhibited similar survivability for both concentrations of paclitaxel. In all of
these samples, the cells exposed to the higher 1µM dose resulted in lower survivability across all
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treatments than the cells exposed to the lower 0.1µM dose. The greatest survivability was
displayed in DMSO samples, but since these cells showed very little difference in ABCB1
expression to either the untreated controls, or the fexofenadine treated cells, the exact reason for
this is unknown. By large margin the weakest survivability was found in vinblastine treated cells
for both paclitaxel concentrations which noticeably varied from all other treatment types. One
possible reason for this greatly diminished survivability may be due to the low yield and poor
health of the vinblastine treated cells on day 49 of their treatment before they were exposed to
paclitaxel. The diminished survival of the vinblastine treated cells towards paclitaxel treatment
could be linked to the high toxicity of vinblastine which already had done considerable damage
to the SKOV-3 population. Additionally, the visible health of the untreated, DMSO, and
fexofenadine treated cells were all relatively at the same. Whether the relative health of the cells
prior to exposure to paclitaxel could be the cause of this variance, however, will require further
investigation to verify as the ABCB1 levels of the cells in each treatment by that time cannot be
verified and thus true causality cannot be assumed.
Altogether, the data from our paclitaxel exposures appears to illustrate an association
between SKOV-3 cells with reduced ABCB1 expression and a degree of paclitaxel resistance as
augmented survivability would indicate reduced sensitivity to the drug’s cytotoxic effects. This
stands in opposition to established and well-described research which indicates that induction of
ABCB1 expression is a viable mechanism for development of resistance to drugs such as
paclitaxel (9, 21, 22). While there are various differing factors which contribute the differences
found in these previous studies, they all contribute knowledge which may help explain the
variance found in our own results. For example, a study performed by Medical University of
Vienna utilized a LS180 colon cancer cell line to verify that anticancer drugs such as paclitaxel
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and vinblastine are shown to induce a PXR-mediated PGP overexpression. Furthermore, it has
been shown that PXR activation is associated with the metabolic reduction of cytotoxic agents,
such as doxorubicin in colon cancer cells (9). This particular study identifies a unique method by
which resistance to doxorubicin is conferred through PXR, while results from additional studies
also suggest that BCB1 activation is a fundamental mechanism for acquired drug resistance to
taxanes, such as paclitaxel in ovarian cancer cells (22). It has also been found that paclitaxel
resistance in SKOV-3 cells is not achieved through the usual PXR-mediated method but rather
through a novel caspase-3 and caspase-9 independent pathway (20). While not a definitive
answer, it does set a precedent that paclitaxel resistance can be achieved in numerous cell types
through methods which have the potential to be unique to each cell type being studied.
In conclusion, the experiments carried out with this ovarian cancer cell line did not
confirm the hypothesis that SKOV-3 cells treated with PGP substrates fexofenadine and
vinblastine could induce ABCB1 gene expression. If further testing were to occur on this project,
then the addition of cells with confirmed PGP induction would be added for a strong positive
control for both aims. Additionally, running a drug dosage curve at the start of the project with
higher concentrations may help ensure that any changes seen in ABCB1 expression within the
cells are actually due to drug exposure rather than other external factors. Finally, it could be
beneficial to run qRT-PCR at multiple points throughout the study, rather than all at once at the
end. This would better qualify the results of the paclitaxel exposure experiment as the test for
resistance would avoid the possible long-term effects of the drugs and for sure utilize cells which
exhibit verified ABCB1 induction.
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Appendix: Linear Regression Coefficients Analysis

Fexofenadine Coefficientsa

Model
1
(Constant)

Unstandardized
Standardized
Coefficients
Coefficients
B
Std. Error
Beta
6.385
.418

Time
-.032
a. Dependent Variable: Fex Study 1

Model
1
(Constant)

-.535

Unstandardized
Standardized
Coefficients
Coefficients
B
Std. Error
Beta
5.331
.255

Time
-.009
a. Dependent Variable: Fex Study 2

Model
1
(Constant)

.025

.011

-.366

Unstandardized
Standardized
Coefficients
Coefficients
B
Std. Error
Beta
8.034
.129

Time
-.041
a. Dependent Variable: Fex Study 3

.006

-.966

t
15.266
-1.267

t
20.893
-.787

t
62.296
-7.471

95.0% Confidence Interval
for B
Sig.
Lower Bound Upper Bound
.000
5.224
7.546
.274

-.103

.038

95.0% Confidence Interval
for B
Sig.
Lower Bound Upper Bound
.000
4.623
6.040
.475

-.039

.022

95.0% Confidence Interval
for B
Sig.
Lower Bound Upper Bound
.000
7.676
8.392
.002

-.057

-.026

DMSO Control Coefficientsa

Model
1
(Constant)

Unstandardized
Standardized
Coefficients
Coefficients
B
Std. Error
Beta
5.444
.625

Time
-.010
a. Dependent Variable: DMSO Study 1

Model
1
(Constant)

-.126

Unstandardized
Standardized
Coefficients
Coefficients
B
Std. Error
Beta
5.238
.342

Time
-.021
a. Dependent Variable: DMSO Study 2

Model
1
(Constant)

.040

.015

-.578

Unstandardized
Standardized
Coefficients
Coefficients
B
Std. Error
Beta
7.652
.258

Time
-.047
a. Dependent Variable: DMSO Study 3

.011

-.906

t
8.705
-.254

t
15.300
-1.417

t
29.713
-4.275

95.0% Confidence Interval
for B
Sig.
Lower Bound Upper Bound
.001
3.708
7.180
.812

-.122

.102

95.0% Confidence Interval
for B
Sig.
Lower Bound Upper Bound
.000
4.287
6.188
.230

-.062

.020

95.0% Confidence Interval
for B
Sig.
Lower Bound Upper Bound
.000
6.937
8.367
.013

-.078

-.017
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Vinblastine Coefficientsa

Model
1
(Constant)

Unstandardized
Standardized
Coefficients
Coefficients
B
Std. Error
Beta
6.462
.454

Time
.076
a. Dependent Variable: Vin Study 1

Model
1
(Constant)

.743

Unstandardized
Standardized
Coefficients
Coefficients
B
Std. Error
Beta
5.646
.291

Time
-.066
a. Dependent Variable: Vin Study 2

Model
1
(Constant)

.040

.013

-.934

Unstandardized
Standardized
Coefficients
Coefficients
B
Std. Error
Beta
8.512
.413

Time
-.019
a. Dependent Variable: Vin Study 3

.018

-.472

t
14.219
1.920

t
19.429
-5.250

t
20.600
-1.071

95.0% Confidence Interval
for B
Sig.
Lower Bound Upper Bound
.001
5.015
7.908
.151

-.050

.202

95.0% Confidence Interval
for B
Sig.
Lower Bound Upper Bound
.000
4.839
6.453
.006

-.101

-.031

95.0% Confidence Interval
for B
Sig.
Lower Bound Upper Bound
.000
7.365
9.660
.345

-.068

.030

